A Prodrug Strategy Using ONYX-015-Based Replicating Adenoviruses to Deliver Rabbit Carboxylesterase to Tumor Cells for Conversion of CPT-11 to SN-38

Cancer Research

Volumn 63, Issue 20, 2003, Pages 6900-6908

  Stubdal, Hilde ^a,c   Perin, Noah ^a,c   Lemmon, Marilyn ^a   Holman, Patricia ^a   Bauzon, Maxine ^a   Potter, Philip M ^b   Danks, Mary K ^b   Fattaey, Ali ^a   Dubensky, Thomas ^a   Johnson, Leisa ^a  

^a ONYX PHARMACEUTICALS   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ADENOVIRUS VECTOR; CARBOXYLESTERASE; IRINOTECAN; ONYX 015; PRODRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; COLON CANCER; CONTROLLED STUDY; DRUG CYTOTOXICITY; ENZYME ACTIVITY; FEMALE; GENE THERAPY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENE; TUMOR XENOGRAFT; VIRUS REPLICATION; WESTERN BLOTTING;

ADENOVIRIDAE; ANIMALS; CAMPTOTHECIN; CARBOXYLESTERASE; COLONIC NEOPLASMS; FEMALE; HUMANS; MICE; MICE, NUDE; PRODRUGS; RABBITS; TRANSGENES; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0142219877     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Ganly, I., Eckhardt, S. G., Rodriguez, G. I., Soutar, D. S., Otto, R., Robertson, A. G., Park, O., Gulley, M. L., Heise, C., Von Hoff, D. D., and Kaye, S. B. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin. Cancer Res., 6: 798-806, 2000.
2. Kirn, D., Hermiston. T., and McCormick F. ONYX-015: clinical data are encouraging. Nat. Med., 4: 1341-1342, 1998.
3. Nemunaitis, J., Ganly, I., Khuri, F., Arsencau, J., Kuhn, J., McCarty, T., Landers, S., Maples, P., Romel, L., Randlev, B., Reid, T., Kaye, S., and Kirn, D. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res., 60: 6359-6366, 2000.
4. Khuri, F. R., Nemunaitis, J., Ganly, I., Arseneau, J., Tannock, I. F., Romel, L., Gore, M., Ironside, J., MacDougall, R. H., Heise, C., Randlev, B., Gillenwater, A. M., Bruso, P., Kaye, S. B., Hong, W. K., and Kirn, D. H. a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat. Med., 6: 879-885, 2000.
5. Ries, S. J., Brandts, C. H., Chung, A. S., Bicderer, C. H., Hann, B. C., Lipner, E. M., McCormick, F., and Michael Korn, W. Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant d11520 (ONYX-015). Nat. Med., 6: 1128-1133, 2000.
6. Heise, C., Sampson-Johannes, A., Williams, A., McCormick, F., Von Hoff, D. D., and Kirn, D. H. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat. Med., 3: 639-645, 1997.
7. You, L., Yang, C. T., and Jablons, D. M. ONYX-015 works synergistically with chemotherapy in lung cancer cell lines and primary cultures freshly made from lung cancer patients. Cancer Res., 60: 1009-1013, 2000.
8. Rogulski, K. R., Freytag, S. O., Zhang, K., Gilbert, J. D., Paielli, D. L., Kirn, J. H., Heise, C. C., and Kirn, D. H. In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy. Cancer Res., 1193-1196, 2000.
9. Petit, T., Davidson, K. K., Cerna, C., Lawrence, R. A., Von Hoff, D. D., Heise, C., Kirn, D., and Izbicka, E. Efficient induction of apoptosis by ONYX-015 adenovirus in human colon cancer cell lines regardless of p53 status. Anticancer Drugs, 13: 47-50, 2002.
10. Chen, S. H., Shine, H. D., Goodman, J. C., Grossman, R. G., and Woo, S. L. Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc. Natl. Acad. Sci. USA, 91: 3054-3057, 1994.
11. Mullen, C. A., Coale, M. M., Lowe, R., and Blaese, R. M. Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild type tumor. Cancer Res., 54: 1503-1506, 1994.
12. Mullen, C. A., Kilstrup, M., and Blaese, R. M. Transfer of the bacterial gene cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc. Natl. Acad. Sci. USA, 89: 33-37, 1992.
13. Manome, Y., Wen, P. Y., Dong, Y., Tanaka, T., Mitchell, B. S., Kufe, D. W. and Fine, H. A. Viral vector transduction of the human deoxycytidine kinase eDNA sensitizes glioma cells to the cytotoxic effects of cytosine arabinoside in vitro and in vivo. Nat. Med., 2: 567-573, 1996.
14. Green, N. K., Youngs, D. J., Neoptolemos, J. P., Friedlos, F., Knox, R. J., Springer, C. J., Anlezark, G. M., Michael, N. P., Melton, R. G., Ford, M. J., Young, L. S., Kerr, D. J., and Searle, P. F. Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-yl)-2, 4-dinitrobenzamide (CB1954) by retroviral transduction and expression of the E. coli nitroreductase gene. Cancer Gene. Ther., 4: 229-238, 1997.
15. Kroetz, D. L., McBride, O. W., and Gonzalez, F. J. Glycosylation-dependent activity of baculovirus-expressed human liver carboxylesterases: cDNA cloning and characterization of two highly similar enzyme forms. Biochemistry, 32: 11606-11617, 1993.
16. Munger, J. S., Shi, G. P., Mark, E. A., Chin, D. T., Gerard, C., and Chapman, H. A. A serine esterase released by human alveolar macrophages is closely related to liver microsomal carboxylesterascs J. Biol. Chem., 266: 18832-18838, 1991.
17. Shibata, F., Takagi, Y., Kitajima, M., Kuroda, T., and Omura, T. Molecular cloning and characterization of a human carboxylesterase gene. Genomics, 17: 76-82, 1993.
18. Kawato, Y., Aonuma, M., Hirota, Y., Kuga, H., and Sato, K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res., 51: 4187-4191, 1991.
19. Tanizawa, A., Fujimori, A., Fujimori, Y., and Pommier, Y. Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J. Natl. Cancer Inst., 86: 836-842, 1994.
20. Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., Elfring, G. L., and Miller, L. L. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N. Engl. J. Med., 343: 905-914, 2000.
21. Douillard, J. Y., Cunningham, D., Roth, A. D., Navarro, M., James, R. D., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alaki, M., Gruia, G., Awad, L., and Rougier, P. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet, 355: 1041-1047, 2000.
22. Rivory, L. P., Haaz, M. C., Canal, P., Lokiec, F., Armand, J. P., and Robert, J. Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase 1/11 trials. Clin. Cancer Res., 3: 1261-1266, 1997.
23. Khanna, R., Morton, C. L., Danks, M. K., and Potter, P. M. Proficient metabolism of irinotecan by a human intestinal carboxylesterase. Cancer Res., 60:4725-4728, 2000.
24. Kojima, A., Hackett, N. R., and Crystal, R. G. Reversal of CPT-11 resistance of lung cancer cells by adenovirus-mediated gene transfer of the human carboxylesterase cDNA. Cancer Res., 58: 4368-4374, 1998.
25. Kojima, A., Hackett, N. R., Ohwada, A., and Crystal, R. G. In vivo human carboxylesterase cDNA gene transfer to activate the prodrug CPT-11 for local treatment of solid tumors. J. Clin. Investig., 101: 1789-1796, 1998.
26. Potter, P. M., Pawlik, C. A., Morton, C. L., Naeve, C. W., and Danks, M. K. Isolation and partial characterization of a cDNA encoding a rabbit liver carboxylesterase that activates the prodrug irinotecan (CPT-11). Cancer Res., 58: 2646-2651, 1998.
27. Wierdl, M., Morton, C. L., Weeks, J. K., Danks, M. K., Harris, L. C., and Potter, P. M. Sensitization of human tumor cells to CPT-11 via adenoviral-mediated delivery of a rabbit liver carboxylesterase. Cancer Res., 61: 5078 -5082, 2001.
28. Danks, M. K., Morton, C. L., Krull, E. J., Cheshiree, P. J., Richmond, L. B., Naeve, C. W., Pawlik, C. A., Houghton, P. J., and Potter, P. M. Comparison of activation of CPT-11 by rabbit and human carboxylesterase for use in enzyme/prodrug therapy. Clin. Cancer Res., 5: 917-924, 1999.
29. Wold, W. S., Doronin, K., Toth, K., Kuppuswamy, M., Lichtenstein, D. L., and Tollefson, A. E. Immune responses to adenoviruses: viral evasion mechanisms and their implications for the clinic. Curr. Opin. Immunol., 11: 380-386, 1999.
30. Hawkins, L. K., Johnson, L., Bauzon, M., Nye, J. A., Castro, D., Kitzes, G. A., Young, M. D., Holt, J. K., Trown, P., and Hermiston, T. W. Gene delivery from the E3 region of replicating human adenovirus: evaluation of the 6.7 K/ gp19 K region. Gene. Ther., 8: 1123-1131, 2001.
31. Hawkins, L. K., and Hermiston, T. W. Gene delivery from the E3 region of replicating human adenovirus: evaluation of the ADP region. Gene. Ther., 8: 1132-1141, 2001.
32. Hawkins, L. K., and Hermiston, T. Gene delivery from the E3 region of replicating human adenovirus: evaluation of the E3B region. Gene. Ther., 8: 1142-1148, 2001.
33. Tollefson, A. E., Hermiston, T. W., and Wold, W. S. Preparation and titration of CsCl-banded adenovirus stock. Methods Mol. Med., 20: 1-9, 1998.
34. Shen, Y., Kitzes, G., Nye, J. A., Fattaey, A., and Hermiston, T. Analyses of single-amino-acid substitution mutants of adenovirus type 5 E1B-55K protein. J. Virol., 75: 4297-4307, 2001.
35. Zamboni, W. C., Stewart, C. F., Cheshire, P. J., Richmond, L. B., Hanna, S. K., Luo, X., Poquette, C., McGovren, J. P., Houghton, J. A., and Houghton, P. J. Studies of the efficacy and pharmacology of irinotecan against human colon tumor xenograft models. Clin. Cancer Res., 4: 743-753, 1998.
36. Zamboni, W. C., Houghton, P. J., Thompson, J., Cheshire, P. J., Hanna, S. K., Richmond, L. B., Lou, X., and Stewart, C. F. Altered irinotecan and SN-38 disposition after intravenous and oral administration of irinotecan in mice bearing human neuroblastoma xenografts. Clin. Cancer Res., 4: 455-462, 1998.
37. Johnson, L., Shen, A., Boyle, L., Kunich, J., Pandey, K., Lemmon, M., Hermiston, T., Giedlin, M., McCormick, F., and Fattaey, A. Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systematic antitumor agents. Cancer Cell., 1: 325-337, 2002.
38. Reid, T., Galanis, E., Abbruzzese, J., Sze, D., Andrews, L., Romel, L., Hatfield, M., Rubin, J., and Kirn, D. Intra-arterial administration of a replication-selective adenovirus (d11520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial. Gene. Ther., 8: 1618-1626, 2001.
39. Sanchez-Prieto, R., Quintanilla, M., Cano, A., Leonart, M. L., Martin, P., Anaya, A., and Ramon y Cajal, S. Carcinoma cell lines become sensitive to DNA-damaging agents by the expression of the adenovirus E1A gene. Oncogene, 13: 1083-1092, 1996.
40. Martin-Duque, P., Sanchez-Prieto, R., Romero, J., Martinez-Lamparero, A., Cebrian-Sagarriga, S., Guinea-Viniegra, J., Dominguez, C., Lleonart, M., Cano, A., Quintanilla, M., and Ramon, Y. C. S. In vivo radiosensitizing effect of the adenovirus E1A gene in murine and human malignant tumors. Int. J. Oncol., 15: 1163-1168, 1999.
41. Schaack, J., Schedl, P., and Shenk, T. Topoisomerase I and II cleavage of adenovirus DNA in vivo: both topoisomerase activities appear to be required for adenovirus DNA replication. J. Virol., 64: 78-85, 1990.
42. Schaak, J., Schedl, P., and Shenk, T. Transcription of adenovirus and HeLa cell genes in the presence of drugs that inhibit topoisomerase I and II function. Nucleic Acids Res., 18: 1499-1508, 1990.
43. Wong, M. L., and Hsu, M. T. Involvement of topoisomerases in replication, transcription, and packaging of the linear adenovirus genome. J. Virol., 64: 691-699, 1990.
44. Morton, C. L., Wierdl, M., Oliver, L., Ma, M. K., Danks, M. K., Stewart, C. F., Eiseman, J. L., and Potter, P. M. Activation of CPT-11 in mice: identification and analysis of a highly effective plasma esterase. Cancer Res., 60: 4206-4210, 2000.